Cargando…

Screening for co-infections in patients with substance use disorders and severe bacterial infections

BACKGROUND: Patients with substance use disorders admitted for severe bacterial infection are in a prime position to be screened for important co-infections. However, data suggest that standard screening for co-infections in this population during hospital admission can vary in frequency and type of...

Descripción completa

Detalles Bibliográficos
Autores principales: Varley, Cara D., Conte, Michael, Streifel, Amber C., Winders, Bradie, Sikka, Monica K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580098/
https://www.ncbi.nlm.nih.gov/pubmed/36277297
http://dx.doi.org/10.1177/20499361221132132
_version_ 1784812320538492928
author Varley, Cara D.
Conte, Michael
Streifel, Amber C.
Winders, Bradie
Sikka, Monica K.
author_facet Varley, Cara D.
Conte, Michael
Streifel, Amber C.
Winders, Bradie
Sikka, Monica K.
author_sort Varley, Cara D.
collection PubMed
description BACKGROUND: Patients with substance use disorders admitted for severe bacterial infection are in a prime position to be screened for important co-infections. However, data suggest that standard screening for co-infections in this population during hospital admission can vary in frequency and type of testing. METHODS: We performed a retrospective review of patients to evaluate screening for co-infections during admission, followed by a case–control analysis to determine factors associated with lack of any screening. RESULTS: We identified 280 patients with 320 eligible admissions. Most were male and Caucasian with unstable housing. Only 67 (23.9%) patients had a primary-care provider. About 89% (n = 250) of our cohort were screened for one or more co-infection during their first admission with one patient never screened despite subsequent admissions. Of those screened, the greatest proportion was HIV (219, 81.4% of those without history of HIV), HCV (94, 79.7% of those without a prior positive HCV antibody), syphilis (206, 73.6%), gonorrhea, and chlamydia (47, 16.8%) with new positive tests identified in 60 (21.4%) people. Screening for all five co-infections was only completed in 15 (14.0%) of the 107 patients who had screening indications. Overall, a high proportion of those screened had a new positive test, including three cases of neurosyphilis, highlighting the importance of screening and treatment initiation. One patient was prescribed HIV pre-exposure prophylaxis at discharge and only 37 (34.6%) of those eligible were referred for HCV treatment or follow-up. In multivariable case–control analysis, non-Medicaid insurance (OR 2.8, 95% CI: 1.2–6.6, p = 0.02), use of only 1 substance (OR 2.9, 95% CI: 1.3–6.5, p < 0.01), and no documented screening recommendations by the infectious disease team (OR 3.7, 95% CI: 1.5–8.8, p < 0.01), were statistically significantly associated with lack of screening for any co-infection during hospital admission. CONCLUSION: Our data suggest additional interventions are needed to improve inpatient screening for co-infections in this population.
format Online
Article
Text
id pubmed-9580098
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-95800982022-10-20 Screening for co-infections in patients with substance use disorders and severe bacterial infections Varley, Cara D. Conte, Michael Streifel, Amber C. Winders, Bradie Sikka, Monica K. Ther Adv Infect Dis Infections Associated with Substance Use and Related Behaviors BACKGROUND: Patients with substance use disorders admitted for severe bacterial infection are in a prime position to be screened for important co-infections. However, data suggest that standard screening for co-infections in this population during hospital admission can vary in frequency and type of testing. METHODS: We performed a retrospective review of patients to evaluate screening for co-infections during admission, followed by a case–control analysis to determine factors associated with lack of any screening. RESULTS: We identified 280 patients with 320 eligible admissions. Most were male and Caucasian with unstable housing. Only 67 (23.9%) patients had a primary-care provider. About 89% (n = 250) of our cohort were screened for one or more co-infection during their first admission with one patient never screened despite subsequent admissions. Of those screened, the greatest proportion was HIV (219, 81.4% of those without history of HIV), HCV (94, 79.7% of those without a prior positive HCV antibody), syphilis (206, 73.6%), gonorrhea, and chlamydia (47, 16.8%) with new positive tests identified in 60 (21.4%) people. Screening for all five co-infections was only completed in 15 (14.0%) of the 107 patients who had screening indications. Overall, a high proportion of those screened had a new positive test, including three cases of neurosyphilis, highlighting the importance of screening and treatment initiation. One patient was prescribed HIV pre-exposure prophylaxis at discharge and only 37 (34.6%) of those eligible were referred for HCV treatment or follow-up. In multivariable case–control analysis, non-Medicaid insurance (OR 2.8, 95% CI: 1.2–6.6, p = 0.02), use of only 1 substance (OR 2.9, 95% CI: 1.3–6.5, p < 0.01), and no documented screening recommendations by the infectious disease team (OR 3.7, 95% CI: 1.5–8.8, p < 0.01), were statistically significantly associated with lack of screening for any co-infection during hospital admission. CONCLUSION: Our data suggest additional interventions are needed to improve inpatient screening for co-infections in this population. SAGE Publications 2022-10-17 /pmc/articles/PMC9580098/ /pubmed/36277297 http://dx.doi.org/10.1177/20499361221132132 Text en © The Author(s), 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Infections Associated with Substance Use and Related Behaviors
Varley, Cara D.
Conte, Michael
Streifel, Amber C.
Winders, Bradie
Sikka, Monica K.
Screening for co-infections in patients with substance use disorders and severe bacterial infections
title Screening for co-infections in patients with substance use disorders and severe bacterial infections
title_full Screening for co-infections in patients with substance use disorders and severe bacterial infections
title_fullStr Screening for co-infections in patients with substance use disorders and severe bacterial infections
title_full_unstemmed Screening for co-infections in patients with substance use disorders and severe bacterial infections
title_short Screening for co-infections in patients with substance use disorders and severe bacterial infections
title_sort screening for co-infections in patients with substance use disorders and severe bacterial infections
topic Infections Associated with Substance Use and Related Behaviors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580098/
https://www.ncbi.nlm.nih.gov/pubmed/36277297
http://dx.doi.org/10.1177/20499361221132132
work_keys_str_mv AT varleycarad screeningforcoinfectionsinpatientswithsubstanceusedisordersandseverebacterialinfections
AT contemichael screeningforcoinfectionsinpatientswithsubstanceusedisordersandseverebacterialinfections
AT streifelamberc screeningforcoinfectionsinpatientswithsubstanceusedisordersandseverebacterialinfections
AT windersbradie screeningforcoinfectionsinpatientswithsubstanceusedisordersandseverebacterialinfections
AT sikkamonicak screeningforcoinfectionsinpatientswithsubstanceusedisordersandseverebacterialinfections